A patient with acute heart failure and renal impairment

BY

AHMAD WAFA, MD.
PROFESSOR OF CARDIOLOGY,
MANSOURA UNIVERSITY

INTRODUCTION

• Cardiac and renal diseases are common and frequently coexist to significantly increase mortality, morbidity, and the complexity and cost of care.

• Primary disorders of 1 of these 2 organs often result in secondary dysfunction or injury to the other. Such interactions represent the pathophysiological basis for a clinical entity called cardiorenal syndrome (CRS).
DEFINITION OF CRS

• CRS can be generally defined as a pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction of one organ may induce acute or chronic dysfunction of the other.

- European Heart Journal (2010) 31, 703–711,

CLASSIFICATION

World congress of nephrology classified cardiorenal syndromes into 5 subtypes based on pathophysiology:

• CRS type 1: acute cardio-renal syndrome
• CRS type 2: chronic cardio-renal syndrome
• CRS type 3: acute reno-cardiac syndrome
• CRS type 4: chronic reno-cardiac syndrome
• CRS type 5: secondary cardio-renal syndrome
**ACUTE CRS**

*CRS type 1 (acute CRS)*-- is characterized by a rapid worsening of cardiac function, leading to acute kidney injury (AKI).

- Acute heart failure (HF) may be divided into 4 subtypes:
  - Hypertensive pulmonary edema with preserved left ventricular (LV) systolic function,
  - Acutely decompensated chronic HF,
  - Cardiogenic shock, and
  - Predominant right ventricular failure

**EPIDEMIOLOGY OF CRS1**

- In the Acute Decompensated Heart Failure National Registry (ADHERE) of 1,05,000 individuals admitted for acute decompensated HF, 30% had a history of renal insufficiency, 21% had serum creatinine concentrations >2.0 mg/dL, and 9% had creatinine concentrations >3.0 mg/dL.
IMPACT OF RENAL DISEASE ON CLINICAL OUTCOMES IN PATIENTS WITH HF

• Renal dysfunction is one of the most important independent risk factors for poor outcomes and all-cause mortality in patients with HF.

• Baseline glomerular filtration rate (GFR) appears to be a stronger predictor of mortality in patients with HF than left ventricular ejection fraction or NYHA functional class.

• Both elevated serum creatinine on admission and worsening creatinine during hospitalization predict prolonged hospitalization, rehospitalization, and death.

PREDICTORS OF WORSENING RENAL FUNCTION IN HF PATIENTS:

In the Studies of Left Ventricular Dysfunction (SOLVD), factors that correlated with worsening renal function (defined as a rise in serum creatinine of 0.3 mg/dL) were:

- Old age
- Low ejection fraction
- Elevated baseline creatinine level
- Low systolic blood pressure
- Diabetes mellitus
- Hypertension
- Use of antiplatelet therapy, diuretics, or beta-blockers
PATHOGENESIS OF CRS1

• The mechanisms by which the onset of acute HF or acutely decompensated chronic HF leads to AKI are multiple and complex.
• The clinical importance of each mechanism is likely to vary from patient to patient (e.g., acute cardiogenic shock vs. hypertensive pulmonary edema) and situation to situation (acute HF secondary to perforation of a mitral valve leaflet from endocarditis vs. worsening right HF secondary to noncompliance with diuretic therapy).

• In acute HF, AKI appears to be more severe in patients with impaired LV ejection fraction compared with those with preserved LV function, achieving an incidence 70% in patients with cardiogenic shock.
• Furthermore, impaired renal function is consistently found as an independent risk factor for 1-year mortality in acute HF patients, including patients with ST-segment elevation myocardial infarction.
PATHOGENESIS OF CRS1

Reduced Cardiac Output → Renal Dysfunction
Increased Central Venous Pressure → Renal Dysfunction
Systemic Inflammation → Renal Dysfunction
Oxidative Stress → Renal Dysfunction

Figure. Proposed pathophysiology of CRS1. A combination of reduced cardiac output, increased central venous pressure, systemic inflammation, and oxidative stress result in renal dysfunction in acute decompensated heart failure.

CRS 1

Hemodynamically mediated damage
Decreased CO
Decreased perfusion
Exogenous factors
Contrast media
ACE inhibitors
Diuretics
Increased venous pressure
Vasodilators
Toxicity
Vasoconstriction

Acute heart disease or procedures
Acute decompensation
Myocardial infarction
Coronary angiography
Cardiac surgery

Humorally mediated damage
RAA activation
Na + H2O retention
Vasoconstriction

Hormonal factors
BNP
Natriuresis

Caspase activation
Apoptosis

Immune mediated damage
Monocyte activation
Endothelial activation

Acute renal injury
Acute hypoperfusion
Reduced oxygen delivery
Necrosis/apoptosis
Decreased GFR
Resistance to ANP/BNP

Biomarkers
KIM-1
Cystatin-C
S-Gal
Creatinine

WHAT TESTS TO PERFORM?

<table>
<thead>
<tr>
<th>Classification</th>
<th>Stage</th>
<th>Definition Based on sCr</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIFLE</td>
<td>Risk</td>
<td>≥ 1.5-fold increase in baseline sCr or decrease in eGFR ≥ 25%</td>
</tr>
<tr>
<td></td>
<td>Injury</td>
<td>≥ 2.0-fold increase in baseline sCr or a decrease in eGFR ≥ 50%</td>
</tr>
<tr>
<td></td>
<td>Failure</td>
<td>≥ 3.0-fold increase in baseline sCr or decrease in eGFR ≥ 75%. If baseline sCr ≥ 4.0 mg/dL, then an increase in sCr of 0.5 mg/dL</td>
</tr>
<tr>
<td>AKIN</td>
<td>1</td>
<td>Increase in sCr ≥ 0.3 mg/dL or 1.5- to 1.9-fold increase in baseline sCr within 48 hours</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2.0- to 2.9-fold increase in baseline sCr</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>≥ 3.0-fold increase in baseline sCr or if baseline sCr ≥ 4 mg/dL, then an increase of ≥ 0.5 mg/dL</td>
</tr>
<tr>
<td>KIDGO</td>
<td>1</td>
<td>≥ 1.5-fold increase in baseline sCr within 7 days or ≥ 0.3 mg/dL, increase within 48 hours</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>≥ 2.0-fold increase in baseline sCr</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>≥ 3.0-fold increase in baseline sCr or an increase to ≥ 4.0 mg/dL</td>
</tr>
</tbody>
</table>

AKIN = acute kidney injury network; KIDGO = kidney disease improving global outcomes; RIFLE = risk, injury, failure, loss of kidney function and end-stage kidney disease; sCr = serum creatinine.

BIOMARKERS OF AKI

In CRS type 1, the early diagnosis of AKI remains a challenge, classic markers such as creatinine increase when AKI is already established and very little can be done to prevent it or to protect the kidney.

- **Neutrophil gelatinase-associated lipocalin (NGAL)**
  appears to be one of the earliest markers detected in the blood and urine of humans with AKI.

- **Kidney injury molecule 1** is a protein detectable in the urine after ischemic or nephrotoxic insults to proximal tubular cells and seems to be highly specific for ischemic AKI.

- **Cystatin C** predicts AKI and the requirement for renal replacement therapy earlier than creatinine.
TREATMENT OF THE CRS
5 IMPORTANT QUESTIONS...

• What is the fluid status?
• Is the BP adequate for renal perfusion?
• What is the cardiac output?
• Is there evidence of high CVP?
• Is there intrinsic renal disease?

Clinical profiles of patients with acute heart failure based on the presence/absence of congestion and/or hypoperfusion
CLINICAL PROFILES OF CRS

<table>
<thead>
<tr>
<th>Profile</th>
<th>Fluid status</th>
<th>CO</th>
<th>SVR</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>To dry</td>
<td>Dry</td>
<td>Low</td>
<td>N or High</td>
<td>Fluids, Stop diuretics</td>
</tr>
<tr>
<td>Too wet</td>
<td>Wet</td>
<td>N</td>
<td>N</td>
<td>Diuretics, aquaretics, Ultrafilteration</td>
</tr>
<tr>
<td>Too clamped</td>
<td>Wet or N</td>
<td>Low</td>
<td>High</td>
<td>ACEI, Nitroprusside, Nesiritide, Seralaxin</td>
</tr>
<tr>
<td>Vasodilated</td>
<td>N or Wet</td>
<td>N or High</td>
<td>Low</td>
<td>Stop VD, Vasopressin, Inotropes</td>
</tr>
<tr>
<td>No pump</td>
<td>Wet</td>
<td>Low</td>
<td>N</td>
<td>Inotropes, vasopressors, LVAD</td>
</tr>
</tbody>
</table>
• The first clinical principle is that the onset of AKI in this setting implies *inadequate renal perfusion* until proven otherwise, which should prompt one to consider the diagnosis of a low cardiac output state and/or marked increase in venous pressure leading to renal congestion.

• The second important consequence of type 1 CRS is *decreased diuretic responsiveness*. In a congestive state, decreased response to diuretics may result from the physiological phenomena of diuretic braking (diminished diuretic effectiveness secondary to postdiuretic sodium retention).

• In addition, concerns of aggravating AKI by the administration of diuretics at greater doses or in combination also can act as an additional, iatrogenic mechanism.

• Diuretics are best provided to HF patients with evidence of systemic fluid overload with the goal of achieving a gradual diuresis.

• Loop diuretics may be titrated according to *renal function*, *systolic blood pressure*, and *history of chronic diuretic use*.

• High doses may cause tinnitus, and a *continuous low-dose diuretic infusion* might be more efficient.
• Measurement of cardiac output (arterial pressure monitoring combined with pulse contour analysis or by Doppler ultrasound) and venous pressure may help ensure adequate and targeted diuretic therapy and allow safer navigation through the precarious situation of combined HF and AKI.

• If diuretic-resistant fluid overload exists despite an optimized cardiac output, removal of isotonic fluid can be achieved by the use of extracorporeal ultrafiltration.

• The presence of AKI with or without concomitant Hyperkalemia may also affect patient outcome by inhibiting the prescription of ACE inhibitors, angiotensin receptor blockers (ARBs), and aldosterone antagonists (drugs that have been shown in large randomized controlled trials to increase survival in the setting of heart failure and myocardial infarction).

• However, provided there is close monitoring of renal function and potassium levels, the potential benefits of these interventions often outweigh their risks, even in these patients.
• The acute administration of beta-blockers in the setting of type 1 CRS generally is not advised. Such therapy should wait until the patient has stabilized physiologically and until concerns about a low output syndrome have been resolved.

• Particular concern applies to beta-blockers excreted by the kidney, such as atenolol or sotalol, alone or in combination with calcium antagonists.

• This should not inhibit the slow, careful, titrated administration of betablockers later on, once patients are hemodynamically stable.

<p>| Table 3. Summary of Treatment Approaches for CRS1 Including Pathophysiology Targeted, Benefits, and Drawbacks |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|</p>
<table>
<thead>
<tr>
<th>Treatment Strategy</th>
<th>Pathophysiology Targeted</th>
<th>Benefits</th>
<th>Drawbacks</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diuretics</td>
<td>Volume overload and elevated CVP</td>
<td>Effective for volume removal</td>
<td>Metabolic derangements</td>
<td>1b</td>
</tr>
<tr>
<td>Nitropes</td>
<td>Reduced cardiac output</td>
<td>May improve renal perfusion in low output state</td>
<td>Increased risk of arrhythmias</td>
<td>5</td>
</tr>
<tr>
<td>Dopamine</td>
<td>Altered renal perfusion</td>
<td>No clear benefits</td>
<td>Increased risk of arrhythmias (tachycardia)</td>
<td>1b</td>
</tr>
<tr>
<td>Nesiritide</td>
<td>Volume overload</td>
<td>No clear benefits</td>
<td>Cost and hypotension</td>
<td>1b</td>
</tr>
<tr>
<td>Adenosine antagonists</td>
<td>Adenosine-mediated renal vasoconstriction</td>
<td>May potentiate diuresis</td>
<td>Not FDA-approved, seizures</td>
<td>1b</td>
</tr>
<tr>
<td>ADH antagonists</td>
<td>Volume overload and hyponatremia</td>
<td>May potentiate diuresis and improve hyponatremia</td>
<td>Costs, no improvements in hard outcomes</td>
<td>1b</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Unknown: Possibly renal perfusion and anti-inflammatory effects</td>
<td>Increased urine output, improved renal function and survival</td>
<td>Hyperglycemia, hypertension, and delirium</td>
<td>1b</td>
</tr>
<tr>
<td>Serelaxin</td>
<td>Unknown: Possibly renal perfusion</td>
<td>Reduced incidence of renal impairment</td>
<td>Not FDA-approved</td>
<td>2b</td>
</tr>
<tr>
<td>Ultrafiltration</td>
<td>Volume overload and elevated CVP</td>
<td>Increased fluid removal as compared to diuretic management</td>
<td>Costs and risks of complications associated with access placement and anticoagulation</td>
<td>1a</td>
</tr>
<tr>
<td>Continuous renal replacement therapy</td>
<td>Volume overload and elevated CVP</td>
<td>No clear benefits</td>
<td>Costs and risks of complications associated with access placement and anticoagulation</td>
<td>2b</td>
</tr>
</tbody>
</table>
TAKE HOME MESSAGES

• The Acute Cardio-Renal Syndrome is a worst case scenario for the CHF patient.
  • Mortality is clearly worsened.
  • Management is difficult.
• Early diagnosis and use of novel biomarker may improve response to therapy.
• Management requires careful balance between volume status, renal perfusion, and intra-renal hemodynamics.

TAKE HOME MESSAGES

• Thoughtful approach to volume management
  • Diuretics high dose and combinations
  • Use ultrafiltration if massive or refractory volume overload
• Many other therapeutic options are tested but its effect on the outcome is lacking
• Many studies are underway testing many therapeutic modalities searching for effective therapy that may improve the gloomy outcome of acute CRS.